CN108883167A - 用于预防和治疗外阴阴道念珠菌病的方法和药剂盒 - Google Patents

用于预防和治疗外阴阴道念珠菌病的方法和药剂盒 Download PDF

Info

Publication number
CN108883167A
CN108883167A CN201780020274.9A CN201780020274A CN108883167A CN 108883167 A CN108883167 A CN 108883167A CN 201780020274 A CN201780020274 A CN 201780020274A CN 108883167 A CN108883167 A CN 108883167A
Authority
CN
China
Prior art keywords
als3
thr
polypeptide
subject
micrograms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780020274.9A
Other languages
English (en)
Chinese (zh)
Inventor
小约翰·E·爱德华兹
斯科特·G·菲勒
小约翰·P·亨尼西
迈克尔·蒂莫西·库克
杰克·D·索贝尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novadigm Therapeutics Inc
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Original Assignee
Los Angeles Biomedical Research Institute at Harbor-Ucla Medical Center
Novadigm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Biomedical Research Institute at Harbor-Ucla Medical Center, Novadigm Therapeutics Inc filed Critical Los Angeles Biomedical Research Institute at Harbor-Ucla Medical Center
Publication of CN108883167A publication Critical patent/CN108883167A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201780020274.9A 2016-03-09 2017-03-07 用于预防和治疗外阴阴道念珠菌病的方法和药剂盒 Pending CN108883167A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662305714P 2016-03-09 2016-03-09
US62/305,714 2016-03-09
PCT/US2017/021094 WO2017155949A1 (en) 2016-03-09 2017-03-07 Methods and kits for use in preventing and treating vulvovaginal candidiasis

Publications (1)

Publication Number Publication Date
CN108883167A true CN108883167A (zh) 2018-11-23

Family

ID=59790870

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780020274.9A Pending CN108883167A (zh) 2016-03-09 2017-03-07 用于预防和治疗外阴阴道念珠菌病的方法和药剂盒

Country Status (5)

Country Link
US (1) US10857216B2 (cg-RX-API-DMAC7.html)
EP (1) EP3426287A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019507759A (cg-RX-API-DMAC7.html)
CN (1) CN108883167A (cg-RX-API-DMAC7.html)
WO (1) WO2017155949A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
EP2734229B1 (en) 2011-07-22 2019-01-02 Novadigm Therapeutics, Inc. Methods and copositions for vaccinating against staphylococcus aureus
BR112015022963A8 (pt) 2013-03-15 2018-01-16 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct composições e métodos para tratar patógenos fúngicos e bacterianos.
WO2017155949A1 (en) 2016-03-09 2017-09-14 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis
JP7439371B2 (ja) * 2018-04-10 2024-02-28 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー- ユーシーエルエー メディカル センター Candida auris感染症の治療方法
EP3552620A1 (en) * 2018-04-11 2019-10-16 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Methods of treatment for candida auris infections
WO2022140646A1 (en) * 2020-12-26 2022-06-30 Mycovia Pharmaceuticals, Inc Dosing regimen for oteseconazole
JP2022191716A (ja) 2021-06-16 2022-12-28 ローム・アンド・ハース・エレクトロニック・マテリアルズ・コリア・リミテッド Uv硬化性シリコーン組成物及びその硬化物

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346074A (en) 1978-08-24 1982-08-24 National Research Development Corp. Pasteurellosis vaccines
US5622939A (en) 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995031998A1 (en) 1994-05-23 1995-11-30 The Research & Development Institute, Inc. Candida albicans adhesin as a vaccine
US5668263A (en) 1994-12-16 1997-09-16 Smithkline Beecham Corporation Conserved yeast nucleic acid sequences
US6500438B2 (en) 1995-06-07 2002-12-31 Pfizer Incorporated In ovo vaccination against coccidiosis
US6288214B1 (en) 1996-05-16 2001-09-11 Texas A&M University Systems Collagen binding protein compositions and methods of use
WO1998009990A1 (en) * 1996-09-04 1998-03-12 Takara Shuzo Co., Ltd. Fungal antigens and process for producing the same
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6248329B1 (en) 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US8541008B2 (en) 1999-11-19 2013-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against candidiasis
US7067138B1 (en) 1999-11-19 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US20060083750A1 (en) 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
JP3717104B2 (ja) 2000-05-30 2005-11-16 シャープ株式会社 回路内蔵受光素子
FR2814741B1 (fr) 2000-09-29 2004-02-27 Atofina Procede de stabilisation de monomeres acryliques
US6579820B2 (en) 2001-03-21 2003-06-17 The Boc Group, Inc. Reactor modifications for NOx reduction from a fluid catalytic cracking regeneration vessel
ES2645563T3 (es) 2001-11-30 2017-12-05 Amgen Fremont Inc. Animales transgénicos que portan genes de cadena ligera de Ig humana
DE10216281B4 (de) 2002-04-12 2007-04-12 Noé, Reinhold, Prof. Dr.-Ing. Anordnung und Verfahren für eine Dispersionsdetektion
CA2486618C (en) 2002-05-21 2013-04-09 Schering-Plough Ltd. Methods for the in vitro culture of sporozoea sp. and uses thereof
US7241613B1 (en) 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
US6935255B2 (en) 2003-08-08 2005-08-30 Deere & Company Auxiliary seed hopper having a removable screen
BRPI0416205A (pt) 2003-11-21 2006-12-26 Pfizer Prod Inc uso de antibióticos como adjuvantes de vacina
US20050287146A1 (en) 2003-12-19 2005-12-29 Joseph Patti Method of inhibiting Candida-related infections using donor selected or donor stimulated immunoglobulin compositions
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
WO2006036817A2 (en) 2004-09-24 2006-04-06 Microbia, Inc. Fungal variants and uses thereof
CA2489194A1 (en) 2004-12-03 2006-06-03 Guilhem Janbon Polypeptides involved in candida biofilm formation and uses thereof
US7971912B2 (en) 2005-04-07 2011-07-05 Sanoh Kogyo Kabushiki Kaisha Quick connector
US7320467B2 (en) 2005-06-03 2008-01-22 Mattel, Inc. Narrating games
WO2007126813A2 (en) 2006-03-29 2007-11-08 Inhibitex, Inc. Cross-reactive monoclonal antibodies recognizing als family proteins
WO2007123850A2 (en) 2006-04-17 2007-11-01 Schering-Plough Ltd. Recombinant attenuated clostridium organisms and vaccine
US8470790B2 (en) 2006-05-04 2013-06-25 Wayne State University Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids
NZ598927A (en) 2007-01-12 2013-09-27 Biocryst Pharm Inc Antiviral nucleoside analogs
WO2008147847A1 (en) 2007-05-22 2008-12-04 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
EP2296698A1 (en) 2008-05-29 2011-03-23 Intervet International BV Coccidiosis vaccines
US20100150942A1 (en) 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
AU2010264538B2 (en) 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
ES2606555T3 (es) 2009-07-03 2017-03-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center HYR1 como objetivo para la inmunización activa y pasiva contra Candida
US9462734B2 (en) 2010-04-27 2016-10-04 Alion Energy, Inc. Rail systems and methods for installation and operation of photovoltaic arrays
EP2403118A3 (en) 2010-07-01 2014-10-29 Kabushiki Kaisha Yaskawa Denki Actuator
KR101075495B1 (ko) 2010-07-06 2011-10-21 주식회사 하이닉스반도체 반도체 모듈에 포함된 다수의 반도체 장치를 선택하는 회로 및 그 동작방법
US20120023753A1 (en) 2010-08-02 2012-02-02 Hao Wen knife having a locking mechanism
WO2012163533A1 (en) 2011-06-01 2012-12-06 Eth Zurich T cell epitope of candida albicans
EP2734229B1 (en) * 2011-07-22 2019-01-02 Novadigm Therapeutics, Inc. Methods and copositions for vaccinating against staphylococcus aureus
AU2012308281A1 (en) 2011-09-14 2014-04-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1-derived compositions and methods of treatment using same
WO2014144024A1 (en) 2013-03-15 2014-09-18 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 compositions and methods for treating fungal and bacterial pathogens
BR112015022963A8 (pt) 2013-03-15 2018-01-16 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct composições e métodos para tratar patógenos fúngicos e bacterianos.
US20160030533A1 (en) 2013-03-15 2016-02-04 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods of treating fungal and bacterial pathogens
GB201503812D0 (en) 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
WO2017155949A1 (en) 2016-03-09 2017-09-14 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ASHRAF S. IBRAHIM等: "NDV-3 Protects Mice From Vulvovaginal Candidiasis Through T-and B-Cell Immune Response", 《VACCINE》 *
CLINT S.SCHMIDT等: "NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus,is safe and immunogenic in healthy adults", 《VACCINE》 *

Also Published As

Publication number Publication date
US10857216B2 (en) 2020-12-08
EP3426287A4 (en) 2020-03-11
JP2019507759A (ja) 2019-03-22
EP3426287A1 (en) 2019-01-16
WO2017155949A1 (en) 2017-09-14
US20190076512A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
US10857216B2 (en) Methods and kits for use in preventing and treating vulvovaginal candidiasis
ES2748381T3 (es) Polipéptido(s) llevado(s) por CYAA y uso para inducir respuestas inmunitarias terapéuticas y profilácticas
AU2011234656B2 (en) Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
JP2020533340A (ja) サポニンを含むリポソーム製剤および使用方法
WO2021216467A1 (en) A nano-enabled vaccination approach for coronavirus disease (covid-19) and other viral diseases
TW201630621A (zh) Kv1.3通道阻斷肽之局部施用以治療皮膚發炎
US20220111028A1 (en) Combination Of A STING Agonist And A Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist
US20250268998A1 (en) Methods of treatment for candida auris infections
JP2019110918A (ja) 真菌病原体および細菌病原体を処置するための組成物および方法
Zhong et al. Nasal delivery of an immunotherapeutic vaccine in thermosensitive hydrogel against allergic asthma
US9707284B2 (en) Formulations of peptides and chloroquines for the treatment of pathogenic immune responses in immune mediated diseases
US20190117749A1 (en) PEPTIDE VACCINE THERAPY FOR TREATMENT OF FRa-EXPRESSING TUMORS
US12180284B2 (en) Clinical methods for use of a PD-L1-binding molecule comprising a Shiga toxin effector
WO2008070902A1 (en) Tgf-beta compositions for treating infertility
AU2018225163A1 (en) Peptides and methods of treating dystrophy-related disorders using the same
EP3552620A1 (en) Methods of treatment for candida auris infections
EP4445910A1 (en) Vaccine composition for inducing anti-il-23 antibody
US20230011870A1 (en) Nanovaccine for heart failure
Jerajani Design and Development of Low-Cost Multi-Dose Human Papillomavirus Vaccine Formulations Containing Antimicrobial Preservatives
US11338025B2 (en) Vaccine therapy for treatment of endometrial and ovarian cancer
HK40015673A (en) Methods of treatment for candida auris infections
AU2013221980A1 (en) Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181123

WD01 Invention patent application deemed withdrawn after publication